Fig. 1 · Structure

Documents & Downloads

Metanicotine

Cat. No. A11545 CAS 15585-43-0

Nicotinic receptor agonist

Metanicotine is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM); > 1,000 fold selectivity than ??7 receptors(Ki= 36000 nM).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Metanicotine Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Metanicotine from 3 published references. In vitro models include lamina V neurons of spinal cord slices prepared from adult rats.

Metanicotine In Vitro Studies

In lamina V neurons of adult rat spinal cord slices, Metanicotine significantly increased sIPSC frequency relative to the pre-application control. In the presence of tetrodotoxin, Metanicotine treatment yielded an mIPSC frequency of 95 ± 3% of the pre-application control. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Spontaneous inhibitory postsynaptic current frequency in rat spinal slices

Cell-based study · lamina V neurons of spinal cord slices prepared from adult rats [1]

In lamina V neurons of adult rat spinal cord slices, Metanicotine perfusion at 100 μM for 1 min significantly increased sIPSC frequency to 573 ± 189% of the pre-application control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
sIPSC frequencysIPSC frequency 573 ± 189% of the control[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Exposure duration
for 1 min
Method
perfusion via a three-way stopcock
Vehicle
Krebs solution
Co-treatment
Other interventions in this design: CNQX 20 μM; APV 50 μM. Compound effect isolated by the comparison: sIPSC frequency before the applications of testing drugs is used as control.
Methods and source locations

Compound reported in the paper: Metanicotine; Compound label in the paper: RJR 2403

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effects of nicotine and nAChR agonists on spontaneous IPSCs in the lamina V neurons (S1, S11, S13, S14); Methods > Patch-clamp recordings from lamina V neurons (S52); Methods > Drug Applications (S53); Figure 2 legend (S75)

sIPSC frequency: sIPSC frequency; comparator: sIPSC frequency before the applications of testing drugs — Results > Effects of nicotine and nAChR agonists on spontaneous IPSCs in the lamina V neurons (S11, S13, S14)

Miniature inhibitory postsynaptic current frequency in rat spinal slices

Cell-based study · lamina V neurons of spinal cord slices prepared from adult rats [1]

In lamina V neurons of adult rat spinal cord slices, Metanicotine was perfused at 100 μM in the presence of tetrodotoxin at 0.5 μM. Under these conditions, mIPSC frequency was 95 ± 3% of the pre-application control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mIPSC frequencymIPSC frequency 100 μM RJR-2403, in the presence of tetrodotoxin (TTX, 0.5 μM): 95 ± 3% of control[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Method
perfusion
Vehicle
Krebs solution
Co-treatment
Other interventions in this design: tetrodotoxin 0.5 μM; CNQX 20 μM; APV 50 μM. Compound effect isolated by the comparison: mIPSC frequency before the applications of testing drugs is used as control.
Reported limits
Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: Metanicotine; Compound label in the paper: RJR 2403

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effects of nicotine and nAChR agonists on spontaneous IPSCs in the lamina V neurons (S1); Results > Effects of nicotine and nAChR agonists on mIPSCs in lamina V neurons (S19, S24, S25); Methods > Patch-clamp recordings from lamina V neurons (S52); Methods > Drug Applications (S53); Figure 3 legend (S81)

mIPSC frequency: mIPSC frequency; comparator: mIPSC frequency before the applications of testing drugs — Results > Effects of nicotine and nAChR agonists on mIPSCs in lamina V neurons (S19, S24, S25)

Metanicotine In Vivo Studies

In wild-type zebrafish, Metanicotine exposure in water had no significant effect on time spent at the bottom of the tank during NTT compared with vehicle control. In mice, Metanicotine injection into the VP significantly reduced mechanical PWT and thermal PWL on both hind paws. [2,3]

Bottom-dwelling behavior in wild-type zebrafish

Animal study · Wild-type zebrafish (Danio rerio; strain AB) [2]

Wild-type zebrafish (Danio rerio; strain AB) were exposed to Metanicotine at 30, 100, and 300 mg/L for 20 min in water. Metanicotine had no significant effect on time spent at the bottom of the tank during NTT compared with vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Time spent at the bottom of the tank during NTTReported result 30, 100, and 300 mg/L: metanicotine had no significant effect.[2]

Conditions shared by the study groups

Route
freely swimming in water containing one of the seven alkaloids
Treatment course
treated with the compounds for 20 min
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Metanicotine 30, 100, and 300 mg/Lvehicle control30, 100, and 300 mg/L: metanicotine had no significant effect.[2]
Metanicotine 30, 100, and 300 mg/L
Model: Wild-type zebrafish (Danio rerio; strain AB)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Metanicotine

Evidence for Metanicotine as the oxalate form reported in the paper, not the free base/neutral form supplied as A11545; no salt equivalence, dose conversion or lot validation.

Materials and methods > Animals (S1); Materials and methods > Zebrafish NTT (S12, S33); Results > Effects of compounds on zebrafish NTT response (S118, S124); Fig. 3 legend (S181, S182, S184)

Time spent at the bottom of the tank during NTT: Time spent at the bottom of the tank during NTT; comparator: vehicle control — Results > Effects of compounds on zebrafish NTT response (S124); Fig. 3 legend (S181, S182)

Metanicotine 30, 100, and 300 mg/L · Materials and methods > Zebrafish NTT (S12, S33); Results > Effects of compounds on zebrafish NTT response (S118, S124); Fig. 3 legend (S182)

Mechanical and thermal responses in mice

Animal study · mice; n = 8 [3]

In mice, Metanicotine at 50 μM, 200 nL was injected into the VP. Mechanical PWT and thermal PWL were significantly reduced on both hind paws following injection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical PWTReported result RJR-2403 (50 μM, 200 nL), into the VP: significantly reduced mechanical PWT and thermal PWL on both hind paws.[3]

Conditions shared by the study groups

Route
into the VP
Treatment course
Behavioral tests were performed 15 min after the mice recovered from anesthesia.
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Metanicotine 50 μM, 200 nLbefore and after injection of RJR-2403 (RJR) into the VPRJR-2403 (50 μM, 200 nL), into the VP: significantly reduced mechanical PWT and thermal PWL on both hind paws.[3]
Metanicotine 50 μM, 200 nL
Model: mice; n = 8
Methods and source locations

Compound reported in the paper: Metanicotine; Compound label in the paper: RJR 2403

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > α4 and α7 subunits in VP neurons are differentially modified in VP neurons (S88, S89); Materials and methods > Pharmacological modulation (S217, S219); Fig 5 legend (S437)

Mechanical PWT: Mechanical PWT; comparator: before and after injection of RJR-2403 (RJR) into the VP — Results > α4 and α7 subunits in VP neurons are differentially modified in VP neurons (S88, S89); Fig 5 legend (S437)

Metanicotine 50 μM, 200 nL · Results > α4 and α7 subunits in VP neurons are differentially modified in VP neurons (S88, S89); Materials and methods > Pharmacological modulation (S219)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 15585-43-0
Applications Nicotinic receptor agonist
Formula C10H14N2
Molecular Weight 162.23
Synonyms Rivanicline; RJR 2403
SMILES
CNCCC=CC1=CN=CC=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Metanicotine Research References

  1. [1] Takeda D, Nakatsuka T, Gu JG, et al. The activation of nicotinic acetylcholine receptors enhances the inhibitory synaptic transmission in the deep dorsal horn neurons of the adult rat spinal cord. Mol Pain (2007). PMID: 17894865 DOI: 10.1186/1744-8069-3-26 Source material
  2. [2] Alzualde A, Jaka O, Latino DARS, et al. Effects of nicotinic acetylcholine receptor-activating alkaloids on anxiety-like behavior in zebrafish. J Nat Med (2021). PMID: 34264421 DOI: 10.1007/s11418-021-01544-8 Source material
  3. [3] Ji YW, Xu XY, Zhou QQ, et al. The subthalamic nucleus-ventral pallidum projection targeting cholinergic circuits modulates chronic pain. PLoS Biol (2026). PMID: 42545964 DOI: 10.1371/journal.pbio.3003923 Source material

Added to your cart

View Cart Checkout
Loading...